Noom Med vs. OrderlyMeds: prices, fine print, and the honest verdict

Tirzepatide pricing

Noom Med does not offer tirzepatide. OrderlyMeds: $299 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Figure is company-stated; we could not capture it on a pricing page.

Semaglutide pricing

On semaglutide, OrderlyMeds wins at $149 versus $199 all-in — $50/mo apart. Noom Med: Semaglutide runs $199 a month all-in — capped at 0.6 mg, a quarter of the trial dose. OrderlyMeds: Semaglutide runs $149 a month all-in.

Transparency

Noom Med: Source-verified (verified 2026-08-08); names its pharmacy — Tailor Made Compounding (named). OrderlyMeds: No price published (verified 2026-08-05); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

Noom Med: 12-week cycles; 12-week billing cycles. OrderlyMeds: none stated; not published.

Two ladders, side by side

Titration is where these pricing structures stop being abstractions: OrderlyMeds holds $299 on every rung (four-month titration: exactly $1,196). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

The semaglutide board

On semaglutide, OrderlyMeds prices at $149 against $199 all-in. Both sit against a verified field floor of $133 and Wegovy's flat $349 brand rate; dual-molecule pricing also sets each program's internal switch cost when a plateau raises the tirzepatide question.

The five normalizations, applied to this pair

1 · All-in, not advertised. Noom Med publishes no figure to normalize; OrderlyMeds's ranked figure is $299, with no membership to add. 2 · Maintenance basis. OrderlyMeds is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. OrderlyMeds: standing $299, no prepaid tier — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. Noom Med: source-verified, read 2026-08-08; OrderlyMeds: no price published, read 2026-08-05. 5 · Pharmacy weighed. Noom Med names Tailor Made Compounding (named); OrderlyMeds names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

Noom Med: no membership — the medication figure is the billed figure; 12-week billing cycles; commitment: 12-week cycles. OrderlyMeds: no membership — the medication figure is the billed figure; not published; commitment: none stated. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

Noom Med carries source-verified pricing (last read 2026-08-08); pharmacy disclosure is its strong suit — Tailor Made Compounding (named), named 503A/503B partner. OrderlyMeds carries no price published pricing (last read 2026-08-05), company-stated rather than page-captured; its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

The switch mechanics are symmetric: new intake, new script, new pharmacy, old plan cancelled in writing. Budget a shipping-gap week, confirm the destination program's price at your current dose (not its starter figure), and if the move is also a molecule change, loop the prescriber in per the switching guide.

Refills, shipping, and the week-to-week reality

Logistics decide more churn than price does, so put them on the record: Noom Med: shipping included; consultation included; async visit model. OrderlyMeds: shipping included; consultation included; async visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick Noom Med if a named pharmacy is non-negotiable for you. Pick OrderlyMeds if the semaglutide line is cheaper here; you want a price that survives titration. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

If neither one fits

Widen the frame one step and the strongest adjacent options are SkinnyRx at $299 (flat, no membership); Amble Health at $300 (flat, no membership); Found at $289 (flat, no membership) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The brand benchmark both must beat

Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $1,800/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.

The verdict

With incomplete published pricing on one or both sides, get current figures in writing before enrolling with either. Both records, with dates and sources, live in the pricing database.